AF
ALLO icon

Advisornet Financial’s Allogene Therapeutics ALLO Stock Holding History

Advisornet Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$426 – 2172
2024
Q4 		$426 Hold
200
– – ﹤0.01% 1802
2024
Q3 		$560 Hold
200
– – ﹤0.01% 2019
2024
Q2 		$466 Sell
200
-20
-9% -$59 ﹤0.01% 1950
2024
Q1 		$983 Hold
220
– – ﹤0.01% 1766
2023
Q4 		$706 Hold
220
– – ﹤0.01% 1999
2023
Q3 		$697 Hold
220
– – ﹤0.01% 1898
2023
Q2 		$1.09K Hold
220
– – ﹤0.01% 1862
2023
Q1 		$1.09K Hold
220
– – ﹤0.01% 1862
2022
Q4 		$1.38K Hold
220
– – ﹤0.01% 1755
2022
Q3 		$2K Hold
220
– – ﹤0.01% 1649
2022
Q2 		$3K Hold
220
– – ﹤0.01% 1592
2022
Q1 		$2K Hold
220
– – ﹤0.01% 1759
2021
Q4 		$3K Hold
220
– – ﹤0.01% 1726
2021
Q3 		$6K Hold
220
– – ﹤0.01% 1565
2021
Q2 		$6K Hold
220
– – ﹤0.01% 1524
2021
Q1 		$8K Hold
220
– – ﹤0.01% 1400
2020
Q4 		$6K Hold
220
– – ﹤0.01% 1396
2020
Q3 		$8K Hold
220
– – ﹤0.01% 1322
2020
Q2 		$9K Buy
+220
New +$7.96K ﹤0.01% 1317

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Advisornet Financial's ALLO Position: Q1 2025 in Review

Advisornet Financial sold out of Allogene Therapeutics (ALLO) in Q1 2025, closing a stake of 200 shares — an estimated $426 sold.

Advisornet Financial first reported a position in ALLO in Q2 2020 and held it in 19 quarters. The position peaked at $9K in Q2 2020. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • Advisornet Financial reported no remaining Allogene Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Advisornet Financial sold 200 Allogene Therapeutics shares in Q1 2025, an estimated $426.
  • Advisornet Financial first reported a position in Allogene Therapeutics in Q2 2020 and held it in 19 quarters.
  • Advisornet Financial's Allogene Therapeutics position peaked at $9K in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on Advisornet Financial's 13F filing for Q1 2025, filed 7 Apr 2025.